...
search icon
lptx-img

Leap Therapeutics Inc, Common Stock

LPTX

NAQ

$0.3802

-$0.03

(-7.23%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$16.58M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
328.32K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.17
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.22 L
$4.79 H
$0.3802

About Leap Therapeutics Inc, Common Stock

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameLPTXSectorS&P500
1-Week Return-4.95%1.9%1.37%
1-Month Return5.73%1.36%15.76%
3-Month Return-21.23%-8.73%-2.58%
6-Month Return-85.32%-5.96%0.72%
1-Year Return-85.21%-7.97%12.24%
3-Year Return-96.75%3.54%52.73%
5-Year Return-98.31%34.17%100.37%
10-Year Return-99.52%78.8%180.28%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue1.50M1.50M375.00K--[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":25,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue--415.00K427.00K-[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":97.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit1.50M1.50M(415.00K)(427.00K)-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-27.67,"profit":false},{"date":"2023-12-31","value":-28.47,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin100.00%100.00%(110.67%)(Infinity%)-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-110.67,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses29.81M41.70M54.71M86.61M70.06M[{"date":"2020-12-31","value":34.41,"profit":true},{"date":"2021-12-31","value":48.14,"profit":true},{"date":"2022-12-31","value":63.17,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":80.88,"profit":true}]
Operating Income(28.54M)(41.43M)(56.76M)(87.04M)(70.06M)[{"date":"2020-12-31","value":-2853900000,"profit":false},{"date":"2021-12-31","value":-4142600000,"profit":false},{"date":"2022-12-31","value":-5676300000,"profit":false},{"date":"2023-12-31","value":-8704100000,"profit":false},{"date":"2024-12-31","value":-7005700000,"profit":false}]
Total Non-Operating Income/Expense1.08M783.00K3.19M9.23M6.22M[{"date":"2020-12-31","value":11.67,"profit":true},{"date":"2021-12-31","value":8.48,"profit":true},{"date":"2022-12-31","value":34.5,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":67.33,"profit":true}]
Pre-Tax Income(27.52M)(40.61M)(54.45M)(81.41M)(66.97M)[{"date":"2020-12-31","value":-2751600000,"profit":false},{"date":"2021-12-31","value":-4061100000,"profit":false},{"date":"2022-12-31","value":-5444900000,"profit":false},{"date":"2023-12-31","value":-8141400000,"profit":false},{"date":"2024-12-31","value":-6697000000,"profit":false}]
Income Taxes(2.00K)(24.00K)147.00K-585.00K[{"date":"2020-12-31","value":-0.34,"profit":false},{"date":"2021-12-31","value":-4.1,"profit":false},{"date":"2022-12-31","value":25.13,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(27.51M)(40.59M)(54.60M)-(67.56M)[{"date":"2020-12-31","value":-2751400000,"profit":false},{"date":"2021-12-31","value":-4058700000,"profit":false},{"date":"2022-12-31","value":-5459600000,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-6755500000,"profit":false}]
Income From Continuous Operations(27.51M)(40.59M)(54.60M)(81.05M)(67.56M)[{"date":"2020-12-31","value":-2751400000,"profit":false},{"date":"2021-12-31","value":-4058700000,"profit":false},{"date":"2022-12-31","value":-5459600000,"profit":false},{"date":"2023-12-31","value":-8105100000,"profit":false},{"date":"2024-12-31","value":-6755500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(27.51M)(40.59M)(54.60M)(81.41M)(67.56M)[{"date":"2020-12-31","value":-2751400000,"profit":false},{"date":"2021-12-31","value":-4058700000,"profit":false},{"date":"2022-12-31","value":-5459600000,"profit":false},{"date":"2023-12-31","value":-8141400000,"profit":false},{"date":"2024-12-31","value":-6755500000,"profit":false}]
EPS (Diluted)(0.55)(0.48)(0.47)(2.20)(0.82)[{"date":"2020-12-31","value":-55,"profit":false},{"date":"2021-12-31","value":-48,"profit":false},{"date":"2022-12-31","value":-47,"profit":false},{"date":"2023-12-31","value":-220,"profit":false},{"date":"2024-12-31","value":-82,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

LPTX
Cash Ratio 2.33
Current Ratio 2.41

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

LPTX
ROA (LTM) -71.81%
ROE (LTM) -142.43%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

LPTX
Debt Ratio Lower is generally better. Negative is bad. 0.40
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.60

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

LPTX
Trailing PE NM
Forward PE NM
P/S (TTM) 160.10
P/B 0.82
Price/FCF NM
EV/R 1.90
EV/Ebitda 0.47
PEG 0.75

FAQs

What is Leap Therapeutics Inc share price today?

Leap Therapeutics Inc (LPTX) share price today is $0.3802

Can Indians buy Leap Therapeutics Inc shares?

Yes, Indians can buy shares of Leap Therapeutics Inc (LPTX) on Vested. To buy Leap Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LPTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Leap Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Leap Therapeutics Inc (LPTX) via the Vested app. You can start investing in Leap Therapeutics Inc (LPTX) with a minimum investment of $1.

How to invest in Leap Therapeutics Inc shares from India?

You can invest in shares of Leap Therapeutics Inc (LPTX) via Vested in three simple steps:

  • Click on Sign Up or Invest in LPTX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Leap Therapeutics Inc shares
What is Leap Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Leap Therapeutics Inc (LPTX) is $4.79. The 52-week low price of Leap Therapeutics Inc (LPTX) is $0.22.

What is Leap Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Leap Therapeutics Inc (LPTX) is 0.82

What is the Market Cap of Leap Therapeutics Inc?

The market capitalization of Leap Therapeutics Inc (LPTX) is $16.58M

What is Leap Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Leap Therapeutics Inc is LPTX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top